In this underpowered RCT, no evidence was found that TXA limits HE nor that it improves clinical outcomes by 90 days in NOAC-associated ICH. That being said, there were no major safety concerns noted
The PATCH-Trauma Trial confirms short-term benefits of tranexamic acid (TXA) for prehospital treatment of the bleeding trauma patient, despite no evidence of long-term functional benefits.